News

Biosign to begin Retail Sales of Pulsewave™

TORONTO, June 11, 2013 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign" or the "Company") made the following statement:

Biosign is pleased to announce the launch of a new e-commerce initiative. For the first time, the general public may now purchase the Health Canada approved Pulsewave™ Monitor system directly from Biosign at store.biosign.com.

Initially two packages will be available: Pulsewave™ Personal ($199.00 + tax & shipping) is designed for one individual user, while Pulsewave™ Family ($229.00 + tax & shipping) is set up in such a way that up to five family members can share the use of one Pulsewave™ Pulse Acquisition Device (PAD). Each Pulsewave™ package includes the innovative Pulsewave™ device and one year of free access to a secure, encrypted online account where the each user's readings, charts & reports are accessible from any web browser.  After the initial free year, a renewal fee of $23.99/year (Personal) or $35.99/year (Family) will be automatically billed to the user for continued access to readings & historical data. Simultaneously, Biosign will also make these Pulsewave™ Personal & Pulsewave™ Family packages available at www.amazon.ca.

New Sales Agent / Value Added Reseller

Biosign has partnered with IBL-Internet Business Logic Inc ("ClinicServer"), a developer of Cloud-based clinical management software, based in Saint John New Brunswick to jointly integrate Biosign's Pulsewave™ health monitor technology and Healthanywhere™ telehealth monitoring platform into ClinicServer's "ClinicServer Flex™" clinical management software solution.  Both ClinicServer and Biosign will sell the resulting integrated package.  Based on the success of the Heart Friendly Dentist program, Biosign actively sought out a partner who could address the rapidly growing market for Allied Health practice optimization solutions. ClinicServer is a genuine pioneer and technology innovator within the Allied Health market.

Biosign Technologies Inc. today announced the following:

Appointment of a new US Sales Agent, opening order of 100 Pulsewave™ devices:

Clear2there LLC, a leading provider of advanced video surveillance, smart-home, smart-business, communications, and machine-to-machine (M2M) solutions for service providers and enterprises, announced it has joined forces with Biosign to address the burgeoning market for smart healthcare and monitoring solutions.

As a part of a sales agency agreement with Biosign, Clear2there will begin offering Biosign's Pulsewave™ medical device technology across the North American market.  Under the terms of the agreement, Clear2there plans to integrate the Pulsewave™ software client with their Viewbiquity Content Interface as well as their Edge Gateway device.  Clear2there will offer the joint solution as a part of a highly-regarded smart services package being delivered to subscribers by local telephone and data service providers across North America. Biosign's FDA-cleared Pulsewave™ monitor captures blood pressure and heart rate readings and will leverage the Viewbiquity Cloud Application Suite provided by Clear2there for connectivity to the Biosign Cloud Diagnostics™ services platform. Initially, Clear2there plans to deploy up to one hundred Pulsewave™ devices and activate the related monitoring services as a part of its ongoing program of service provider evaluation currently underway in over 65 Viewbiquity pilot projects in the United States.

Biosign Technologies Inc. today announced the following:

Changes to the Board of Directors:

Biosign announces the resignation of directors Mr. Jason Meretsky and Senator Alfonse D'Amato, effective immediately. Mr. Meretsky and Senator D'Amato are leaving the Board in order to devote time to their other business interests. The Board and management wish to sincerely thank both directors for their dedicated service. They have helped lead Biosign through a challenging period of restructuring and their advice and counsel have been instrumental in allowing the Company to succeed. We wish them both great success in all their future endeavors.

Biosign is pleased to announce the appointment of two new directors:

Dr. Sandeep (Sonny) Kohli is an attending Physician in the Intensive Care Department of Oakville Trafalgar Memorial Hospital and Assistant Clinical Professor (Adjunct) of Medicine at McMaster University. He is also the Medical Director, ACLS, at the Michener Institute for Applied Health Sciences and President of Triomi Medical Innovations Inc. From May 2008 to March 2009 Dr. Kohli was an Astronaut Candidate at the Canadian Space Agency (CSA), where he was awarded a Scholarship by the CSA as a Critical Care Medicine fellow to go to Johnson Space Center and partake in aerospace medical research activities. Dr. Kohli has also been appointed as Medical Director for Biosign.  He is highly knowledgeable regarding Biosign's Pulsewave™ product, having previously served as a medical advisor to BioAnalytics Inc., a Biosign distribution partner.

Mr. Dennis Rygwalski is a senior financial services & technology executive recognized for leading best-of-class enterprise IT and bank operations organizations. He is currently the founder of D. Rygwalsky & Associates Inc., a Tulsa, Oklahoma management consulting firm to the financial services and technology sectors.  Until 2012 he served as EVP Technology & Chief Information Officer for Western Alliance Bancorp, a $7 billion commercial multi-bank holding company based in Phoenix, Arizona, and before that he held the positions of Chief Technology Officer for the Bank of Oklahoma, a $25 billion financial services group (2006-2011), head of Finance Industry Solutions for Boston-based technology provider Exigen Group (2001-2005), and Chief Information Officer for Fleet Boston Financial, a $180 billion diversified banking and financial services company acquired by Bank of America in 2004 (1988-2001).

Biosign Technologies Inc. announced that during the month of February, 2013 in partnership with sales agent Dominion Medical, Biosign achieved 100% retention of the Heart Friendly™ Dentist customer accounts up for renewal during that month. As previously announced February 4^th, 2013, Biosign will donate a percentage of the proceeds from each Heart Friendly™ Dentist enrollment during the month of February to the Heart & Stroke Foundation of Canada (the "Foundation").

Based on the successful Heart Month promotion, Biosign announced the expansion of the Heart Friendly™ program beyond the dental industry. Starting in April 2013, the Company will begin marketing to two new sectors: Heart Friendly™ Practice will market the brand to "allied health professionals" including optometrists, doctors of naturopathy, physical therapists and wellness practitioners. Heart Friendly™ Fitness will market the program to gyms, fitness centers and health spas. This expansion further aligns the Heart Friendly™ program with the goals of heart healthy charities like the Heart & Stroke Foundation. Their "Make Health Last" campaign aims to educate Canadians on the lasting benefits of changing to a healthy lifestyle. The Foundation supports the Heart Friendly mission to screen Canadians at places they may frequent much more often than a doctor's office: the dentist, the eye doctor, or the gym.

Biosign Technologies Inc. (TSXV: BIO) ("Biosign" or the "Company") today annonced the following:

Restatement of the Engagement of Mr. Peter Hamilton: With respect to the previously announced appointment of Mr. Peter Hamilton to the position of Executive Vice President of Business Development of the Company on December 21, 2012, due to a revision in the Company's restructuring plan, Mr. Hamilton's relationship with the Company has been changed. Rosseau Consulting Inc., of which Mr. Hamilton is an employee, has been retained as a consultant to provide business development services to the Company. As part of such services, Mr. Hamilton will assist in the provision of such services with the title of Business Development Consultant. As a result, Mr. Hamilton is not an executive or employee of the Company and his relationship to Biosign is that of an independent consultant.

Biosign Technologies Inc. (TSXV: BIO) ("Biosign" or the "Company") announced several important achievements as it proceeds with its restructuring plan:

BIOSIGN APPOINTS SALES AGENT TO THE CANADIAN DENTAL MARKET. Dominion Medical Supply Inc ("Dominion"), a Dunville, ON-based specialty medical/dental sales agent, has been appointed to represent Biosign products to the Canadian dental market. Dominion represents a number of high-tech products, including disposable supplies as well as specialized magnifying lenses, to dentists in Ontario, Quebec and the Maritimes. The advanced nature of the products sold by Dominion typically involves extended interview time on each sales call to dentist and dental hygienist customers, which positions Dominion's team to detail the benefits offered by Biosign's health monitoring products.

BIOSIGN & DOMINION RE-LAUNCH "HEART FRIENDLY™ DENTIST" AND SUPPORT THE HEART & STROKE FOUNDATION DURING "HEART MONTH". In December 2012, Biosign acquired the assets of Bioanalytics Inc (see press release dated December 7^th, 2012) including the brand name "Heart Friendly™" and associated marketing assets.

The Company announced the re-launch of the Heart Friendly™ Dentist program in Ontario. Dentists who enroll in the Heart Friendly™ Dentist program typically purchase a Biosign Pulsewave™ monitor for each exam room or dental hygiene station, and then also pay a monthly or annual fee for Biosign's Cloud Diagnostics™ readings and a free, printable Heart Friendly™ Health Reportthat they can print for each patient to take home. Dentists have commented that the Heart Friendly™ program gives them an additional valuable service to offer their patients, helps them differentiate their practice from their competition, and even assists them in identifying patients at immediate risk who may need medical attention. In a brief test-market campaign in 2012, Bioanalytics enrolled over 50 Toronto-area clinics in the Heart Friendly™ program, and many of these customers are now renewing their enrollment agreements with Biosign for either one or two year commitments.

During Heart Month (February 2013) Biosign has agreed to donate 5% of the net proceeds from each Toronto-area enrollment in the Heart Friendly™ Dentist program to the Heart & Stroke Foundation. Additionally, Heart Friendly™ Dentists will be able to distribute timely information from the Heart & Stroke Foundation to their patients along with a Heart Friendly™ Health Report, powered by Biosign.

Biosign Technologies Inc. (TSXV: BIO) (the “Company”) announced today an amendment to the scheduled closing applicable to an additional subscription of 6,000,000 units of the Company (the “Units”) at a purchase price of $0.05 per Unit, which formed part of its previously announced private placement financing (see news releases issued on November 29, 2012 and December 21, 2012).  Each Unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant is exercisable for a two-year period at $0.05 per share during the first 12 months and $0.10 per share in the second twelve months.

Biosign Technologies Inc. (TSXV: BIO) (the "Company") is pleased to announce that on December 31st, 2012 it closed a private placement for 3,936,100 units of the Company (the "Units") at a purchase price of $0.05 per Unit, in addition to the previously announced placement (see news December 21, 2012) which forms part of its recently announced private placement financing (see news November 29, 2012) as approved by the Company's Board of Directors.  No director has an interest in the private placement. Each Unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant is exercisable for a 2-year period at $0.05 per share during the first twelve months and $0.10 per share in the second twelve months. The securities issued in connection with the Offering are subject to a four-month hold period from the issuance date in accordance with the policies of the TSXV and applicable securities laws.

The Company is obliged to pay finders' fees to certain independent brokers on certain subscriptions under this placement in the amount of 749,288 units on the same terms as the units noted above. Such units shall be issued as the Company receives certain phased subscription proceeds (see news December 21, 2012).